{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:04:04Z","timestamp":1790643844842,"version":"4.1.0"},"reference-count":100,"publisher":"Siapec Servizi Srl","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologica"],"DOI":"10.32074\/1591-951x-351","type":"journal-article","created":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T09:48:03Z","timestamp":1638006483000},"page":"339-353","source":"Crossref","is-referenced-by-count":25,"title":["Multicentric Castleman disease and the evolution of the concept"],"prefix":"10.32074","volume":"113","author":[{"given":"Ting","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Pittaluga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine S.","family":"Jaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21774","published-online":{"date-parts":[[2021,10]]},"reference":[{"key":"10.32074\/1591-951X-351_ref1","doi-asserted-by":"crossref","unstructured":"Castleman B, Towne VW. Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot. N Engl J Med 1954;251:396-400. https:\/\/doi.org\/10.1056\/NEJM195409022511008.","DOI":"10.1056\/NEJM195409022511008"},{"key":"10.32074\/1591-951X-351_ref2","doi-asserted-by":"crossref","unstructured":"Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972;29:670-683. doi:10.1002\/1097-0142(197203)29:3<670::aid-cncr2820290321>3.0.co;2-#.","DOI":"10.1002\/1097-0142(197203)29:3<670::AID-CNCR2820290321>3.0.CO;2-#"},{"key":"10.32074\/1591-951X-351_ref3","doi-asserted-by":"crossref","unstructured":"Frizzera G, Banks PM, Massarelli G, et al. A systemic lymphoproliferative disorder with morphologic features of Castleman\u2019s disease. Pathological findings in 15 patients. Am J Surg Pathol 1983;7:211-231. https:\/\/doi.org\/10.1097\/00000478-198304000-00001","DOI":"10.1097\/00000478-198304000-00001"},{"key":"10.32074\/1591-951X-351_ref4","doi-asserted-by":"crossref","unstructured":"Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease. Blood 2017;129:1646-1657. Epub 2017 Jan 13. https:\/\/doi.org\/10.1182\/blood-2016-10-746933","DOI":"10.1182\/blood-2016-10-746933"},{"key":"10.32074\/1591-951X-351_ref5","doi-asserted-by":"crossref","unstructured":"Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi\u2019s sarcoma. Science 1994;266:1865-1869. https:\/\/doi.org\/10.1126\/science.7997879","DOI":"10.1126\/science.7997879"},{"key":"10.32074\/1591-951X-351_ref6","doi-asserted-by":"crossref","unstructured":"Soulier J, Grollet L, Oksenhendler E, et al. Kaposi\u2019s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman\u2019s disease. Blood 1995;86:1276-1280.","DOI":"10.1182\/blood.V86.4.1276.bloodjournal8641276"},{"key":"10.32074\/1591-951X-351_ref7","doi-asserted-by":"crossref","unstructured":"Cesarman E, Chang Y, Moore PS, et al. Kaposi\u2019s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995;332:1186-1191. https:\/\/doi.org\/10.1056\/NEJM199505043321802","DOI":"10.1056\/NEJM199505043321802"},{"key":"10.32074\/1591-951X-351_ref8","doi-asserted-by":"crossref","unstructured":"Rohner E, Wyss N, Trelle S, et al. HHV-8 seroprevalence: a global view. Syst Rev 2014;3:11. https:\/\/doi.org\/10.1186\/2046-4053-3-11.","DOI":"10.1186\/2046-4053-3-11"},{"key":"10.32074\/1591-951X-351_ref9","doi-asserted-by":"crossref","unstructured":"Brousset P, Cesarman E, Meggetto F, et al. Colocalization of the viral interleukin-6 with latent nuclear antigen-1 of human herpesvirus-8 in endothelial spindle cells of Kaposi\u2019s sarcoma and lymphoid cells of multicentric Castleman\u2019s disease. Hum Pathol 2001;32:95-100. https:\/\/doi.org\/10.1053\/hupa.2001.21131","DOI":"10.1053\/hupa.2001.21131"},{"key":"10.32074\/1591-951X-351_ref10","doi-asserted-by":"crossref","unstructured":"Gunther T, Grundhoff A: The epigenetic landscape of latent Kaposi sarcoma-associated herpesvirus genomes. PLoS Pathog 2010;6:e1000935. https:\/\/doi.org\/10.1371\/journal.ppat.1000935","DOI":"10.1371\/journal.ppat.1000935"},{"key":"10.32074\/1591-951X-351_ref11","doi-asserted-by":"crossref","unstructured":"Guito J, Lukac DM: KSHV reactivation and novel implications of protein isomerization on lytic switch control. Viruses 2015;7:72-109. https:\/\/doi.org\/10.3390\/v7010072","DOI":"10.3390\/v7010072"},{"key":"10.32074\/1591-951X-351_ref12","doi-asserted-by":"crossref","unstructured":"Hughes DJ, Wood JJ, Jackson BR, et al. NEDDylation is essential for Kaposi\u2019s sarcoma-associated herpesvirus latency and lytic reactivation and represents a novel anti-KSHV target. PLoS Pathog 2015;11:e1004771. https:\/\/doi.org\/10.1371\/journal.ppat.1004771","DOI":"10.1371\/journal.ppat.1004771"},{"key":"10.32074\/1591-951X-351_ref13","doi-asserted-by":"crossref","unstructured":"Pantry SN, Medveczky PG: Epigenetic regulation of Kaposi\u2019s sarcoma-associated herpesvirus replication. Semin Cancer Biol 2009;19:153-157. https:\/\/doi.org\/10.1016\/j.semcancer.2009.02.010.","DOI":"10.1016\/j.semcancer.2009.02.010"},{"key":"10.32074\/1591-951X-351_ref14","doi-asserted-by":"crossref","unstructured":"Toth Z, Maglinte DT, Lee SH, et al. Epigenetic analysis of KSHV latent and lytic genomes. PLoS Pathog 2010;6:e1001013. https:\/\/doi.org\/10.1371\/journal.ppat.1001013","DOI":"10.1371\/journal.ppat.1001013"},{"key":"10.32074\/1591-951X-351_ref15","doi-asserted-by":"crossref","unstructured":"Yu X, Shahir AM, Sha J, et al. Short-chain fatty acids from periodontal pathogens suppress histone deacetylases, EZH2, and SUV39H1 to promote Kaposi\u2019s sarcoma-associated herpesvirus replication. J Virol 2014;88:4466-4479. Epub 2014 Feb 5. https:\/\/doi.org\/10.1128\/JVI.03326-13","DOI":"10.1128\/JVI.03326-13"},{"key":"10.32074\/1591-951X-351_ref16","doi-asserted-by":"crossref","unstructured":"Chang H, Dittmer DP, Shin YC, et al. Role of Notch signal transduction in Kaposi\u2019s sarcoma-associated herpesvirus gene expression. J Virol 2005;79:14371-14382. https:\/\/doi.org\/10.1128\/JVI.79.22.14371-14382.2005","DOI":"10.1128\/JVI.79.22.14371-14382.2005"},{"key":"10.32074\/1591-951X-351_ref17","doi-asserted-by":"crossref","unstructured":"Hu D, Wang V, Yang M, et al. Induction of Kaposi\u2019s Sarcoma-Associated Herpesvirus-Encoded Viral Interleukin-6 by X-Box Binding Protein 1. J Virol 2016;90:368-378. https:\/\/doi.org\/10.1128\/JVI.01192-15","DOI":"10.1128\/JVI.01192-15"},{"key":"10.32074\/1591-951X-351_ref18","doi-asserted-by":"crossref","unstructured":"Katano H, Sato Y, Kurata T, et al. Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi\u2019s sarcoma, and multicentric Castleman\u2019s disease. Virology 2000;269:335-344. https:\/\/doi.org\/10.1006\/viro.2000.0196","DOI":"10.1006\/viro.2000.0196"},{"key":"10.32074\/1591-951X-351_ref19","doi-asserted-by":"crossref","unstructured":"Parravicini C, Chandran B, Corbellino M, et al. Differential viral protein expression in Kaposi\u2019s sarcoma-associated herpesvirus-infected diseases: Kaposi\u2019s sarcoma, primary effusion lymphoma, and multicentric Castleman\u2019s disease. Am J Pathol 2000;156:743-749. https:\/\/doi.org\/10.1016\/S0002-9440(10)64940-1","DOI":"10.1016\/S0002-9440(10)64940-1"},{"key":"10.32074\/1591-951X-351_ref20","doi-asserted-by":"crossref","unstructured":"Wan X, Wang H, Nicholas J: Human herpesvirus 8 interleukin-6 (vIL-6) signals through gp130 but has structural and receptor-binding properties distinct from those of human IL-6. J Virol 1999;73:8268-8278. https:\/\/doi.org\/10.1128\/JVI.73.10.8268-8278.1999","DOI":"10.1128\/JVI.73.10.8268-8278.1999"},{"key":"10.32074\/1591-951X-351_ref21","doi-asserted-by":"crossref","unstructured":"Fajgenbaum DC: Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. Blood 2018;132:2323-2330. https:\/\/doi.org\/10.1182\/blood-2018-05-848671.","DOI":"10.1182\/blood-2018-05-848671"},{"key":"10.32074\/1591-951X-351_ref22","doi-asserted-by":"crossref","unstructured":"Coscoy L. Immune evasion by Kaposi\u2019s sarcoma-associated herpesvirus. Nat Rev Immunol 2007;7:391-401. https:\/\/doi.org\/10.1038\/nri2076","DOI":"10.1038\/nri2076"},{"key":"10.32074\/1591-951X-351_ref23","doi-asserted-by":"crossref","unstructured":"Moore PS, Boshoff C, Weiss RA, et al. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 1996;274:1739-1744. https:\/\/doi.org\/10.1126\/science.274.5293.1739","DOI":"10.1126\/science.274.5293.1739"},{"key":"10.32074\/1591-951X-351_ref24","doi-asserted-by":"crossref","unstructured":"Polizzotto MN, Uldrick TS, Wang V, et al. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood 2013;122:4189-4198. https:\/\/doi.org\/10.1182\/blood-2013-08-519959","DOI":"10.1182\/blood-2013-08-519959"},{"key":"10.32074\/1591-951X-351_ref25","doi-asserted-by":"crossref","unstructured":"Aoki Y, Tosato G, Fonville TW, et al. Serum viral interleukin-6 in AIDS-related multicentric Castleman disease. Blood 2001;97:2526-2527. https:\/\/doi.org\/10.1182\/blood.v97.8.2526","DOI":"10.1182\/blood.V97.8.2526"},{"key":"10.32074\/1591-951X-351_ref26","doi-asserted-by":"crossref","unstructured":"Neipel F, Albrecht JC, Ensser A, et al. Human herpesvirus 8 encodes a homolog of interleukin-6. J Virol 1997;71:839-842. https:\/\/doi.org\/10.1128\/JVI.71.1.839-842.1997","DOI":"10.1128\/jvi.71.1.839-842.1997"},{"key":"10.32074\/1591-951X-351_ref27","doi-asserted-by":"crossref","unstructured":"Aoki Y, Jones KD, Tosato G. Kaposi\u2019s sarcoma-associated herpesvirus-encoded interleukin-6. J Hematother Stem Cell Res 2000;9:137-145. https:\/\/doi.org\/10.1089\/152581600319351","DOI":"10.1089\/152581600319351"},{"key":"10.32074\/1591-951X-351_ref28","doi-asserted-by":"crossref","unstructured":"Osborne J, Moore PS, Chang Y: KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways. Hum Immunol 1999;60:921-927. https:\/\/doi.org\/10.1016\/s0198-8859(99)00083-x","DOI":"10.1016\/S0198-8859(99)00083-X"},{"key":"10.32074\/1591-951X-351_ref29","doi-asserted-by":"crossref","unstructured":"Boulanger MJ, Chow DC, Brevnova E, et al. Molecular mechanisms for viral mimicry of a human cytokine: activation of gp130 by HHV-8 interleukin-6. J Mol Biol 2004;335:641-654. https:\/\/doi.org\/10.1016\/j.jmb.2003.10.070","DOI":"10.1016\/j.jmb.2003.10.070"},{"key":"10.32074\/1591-951X-351_ref30","doi-asserted-by":"crossref","unstructured":"Li H, Nicholas J. Identification of amino acid residues of gp130 signal transducer and gp80 alpha receptor subunit that are involved in ligand binding and signaling by human herpesvirus 8-encoded interleukin-6. J Virol 2002;76:5627-5636. https:\/\/doi.org\/10.1128\/jvi.76.11.5627-5636.2002","DOI":"10.1128\/JVI.76.11.5627-5636.2002"},{"key":"10.32074\/1591-951X-351_ref31","doi-asserted-by":"crossref","unstructured":"Scheller J, Chalaris A, Schmidt-Arras D, et al. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011;1813:878-888. https:\/\/doi.org\/10.1016\/j.bbamcr.2011.01.034","DOI":"10.1016\/j.bbamcr.2011.01.034"},{"key":"10.32074\/1591-951X-351_ref32","doi-asserted-by":"crossref","unstructured":"Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008;112:3959-3964. https:\/\/doi.org\/10.1182\/blood-2008-05-155846","DOI":"10.1182\/blood-2008-05-155846"},{"key":"10.32074\/1591-951X-351_ref33","doi-asserted-by":"crossref","unstructured":"Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6\/BSF-2) in Castleman\u2019s disease. Blood 1989;74:1360-1367.","DOI":"10.1182\/blood.V74.4.1360.bloodjournal7441360"},{"key":"10.32074\/1591-951X-351_ref34","doi-asserted-by":"crossref","unstructured":"Kagan P, Sultan M, Tachlytski I, et al. Both MAPK and STAT3 signal transduction pathways are necessary for IL-6-dependent hepatic stellate cells activation. PLoS One 2017;12:e0176173. https:\/\/doi.org\/10.1371\/journal.pone.0176173","DOI":"10.1371\/journal.pone.0176173"},{"key":"10.32074\/1591-951X-351_ref35","doi-asserted-by":"crossref","unstructured":"Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood 2000;96:2069-2073.","DOI":"10.1182\/blood.V96.6.2069"},{"key":"10.32074\/1591-951X-351_ref36","doi-asserted-by":"crossref","unstructured":"Bower M, Veraitch O, Szydlo R, et al. Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease. Blood 2009;113:4521-4524. https:\/\/doi.org\/10.1182\/blood-2008-12-197053","DOI":"10.1182\/blood-2008-12-197053"},{"key":"10.32074\/1591-951X-351_ref37","doi-asserted-by":"crossref","unstructured":"Suda T, Katano H, Delsol G, et al. HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman\u2019s disease. Pathol Int 2001;51:671-679. https:\/\/doi.org\/10.1046\/j.1440-1827.2001.01266.x","DOI":"10.1046\/j.1440-1827.2001.01266.x"},{"key":"10.32074\/1591-951X-351_ref38","doi-asserted-by":"crossref","unstructured":"Pinzone MR, Berretta M, Cacopardo B, et al. Epstein-barr virus- and Kaposi sarcoma-associated herpesvirus-related malignancies in the setting of human immunodeficiency virus infection. Semin Oncol 2015;42:258-271. https:\/\/doi.org\/10.1053\/j.seminoncol.2014.12.026","DOI":"10.1053\/j.seminoncol.2014.12.026"},{"key":"10.32074\/1591-951X-351_ref39","doi-asserted-by":"crossref","unstructured":"Quinlivan EB, Zhang C, Stewart PW, et al. Elevated virus loads of Kaposi\u2019s sarcoma-associated human herpesvirus 8 predict Kaposi\u2019s sarcoma disease progression, but elevated levels of human immunodeficiency virus type 1 do not. J Infect Dis 2002;185:1736-1744. https:\/\/doi.org\/10.1086\/340652","DOI":"10.1086\/340652"},{"key":"10.32074\/1591-951X-351_ref40","doi-asserted-by":"crossref","unstructured":"Kurzrock R, Voorhees PM, Casper C, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res 2013;19:3659-3670. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3349","DOI":"10.1158\/1078-0432.CCR-12-3349"},{"key":"10.32074\/1591-951X-351_ref41","doi-asserted-by":"crossref","unstructured":"Uldrick TS, Polizzotto MN, Aleman K, et al. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. Blood 2014;124:3544-3552. https:\/\/doi.org\/10.1182\/blood-2014-07-586800","DOI":"10.1182\/blood-2014-07-586800"},{"key":"10.32074\/1591-951X-351_ref42","doi-asserted-by":"crossref","unstructured":"Stary G, Kohrgruber N, Herneth AM, et al. Complete regression of HIV-associated multicentric Castleman disease treated with rituximab and thalidomide. AIDS 2008;22:1232-1234. https:\/\/doi.org\/10.1097\/QAD.0b013e3282fa75ce","DOI":"10.1097\/QAD.0b013e3282fa75ce"},{"key":"10.32074\/1591-951X-351_ref43","doi-asserted-by":"crossref","unstructured":"Oksenhendler E, Boutboul D, Fajgenbaum D, et al. The full spectrum of Castleman disease: 273 patients studied over 20 years, Br J Haematol 2018;180:206-216. https:\/\/doi.org\/10.1111\/bjh.15019","DOI":"10.1111\/bjh.15019"},{"key":"10.32074\/1591-951X-351_ref44","doi-asserted-by":"crossref","unstructured":"Polizzotto MN, Uldrick TS, Wyvill KM, et al. Clinical features and outcomes of patients with symptomatic kaposi sarcoma herpesvirus (kshv)-associated inflammation: prospective characterization of KSHV Inflammatory Cytokine Syndrome (KICS). Clin Infect Dis 2016;62:730-738. https:\/\/doi.org\/10.1093\/cid\/civ996","DOI":"10.1093\/cid\/civ996"},{"key":"10.32074\/1591-951X-351_ref45","doi-asserted-by":"crossref","unstructured":"Uldrick TS, Wang V, O\u2019Mahony D, et al. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease. Clin Infect Dis 2010;51:350-358. https:\/\/doi.org\/10.1086\/654798","DOI":"10.1086\/654798"},{"key":"10.32074\/1591-951X-351_ref46","doi-asserted-by":"crossref","unstructured":"Connick E, Kane MA, White IE, et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy. Clin Infect Dis 2004;39:1852-1855. https:\/\/doi.org\/10.1086\/426078","DOI":"10.1086\/426078"},{"key":"10.32074\/1591-951X-351_ref47","doi-asserted-by":"crossref","unstructured":"Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 2002;99:2331-2336. https:\/\/doi.org\/10.1182\/blood.v99.7.2331","DOI":"10.1182\/blood.V99.7.2331"},{"key":"10.32074\/1591-951X-351_ref48","doi-asserted-by":"crossref","unstructured":"Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000;95:1406-1412.","DOI":"10.1182\/blood.V95.4.1406.004k26_1406_1412"},{"key":"10.32074\/1591-951X-351_ref49","doi-asserted-by":"crossref","unstructured":"Du MQ, Liu H, Diss TC, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 2001;97:2130-2136. https:\/\/doi.org\/10.1182\/blood.v97.7.2130","DOI":"10.1182\/blood.V97.7.2130"},{"key":"10.32074\/1591-951X-351_ref50","unstructured":"Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised Fourth Edition. Edited by Lyon, France, International Agency for Research on Cancer 2017."},{"key":"10.32074\/1591-951X-351_ref51","doi-asserted-by":"crossref","unstructured":"Derudder E, Cadera EJ, Vahl JC, et al. Development of immunoglobulin lambda-chain-positive B cells, but not editing of immunoglobulin kappa-chain, depends on NF-kappaB signals. Nat Immunol 2009;10:647-654. https:\/\/doi.org\/10.1038\/ni.1732","DOI":"10.1038\/ni.1732"},{"key":"10.32074\/1591-951X-351_ref52","doi-asserted-by":"crossref","unstructured":"Weisenburger DD, Nathwani BN, Winberg CD, et al. Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol 1985;16:162-172. https:\/\/doi.org\/10.1016\/s0046-8177(85)80065-4","DOI":"10.1016\/S0046-8177(85)80065-4"},{"key":"10.32074\/1591-951X-351_ref53","doi-asserted-by":"crossref","unstructured":"Chadburn A, Said J, Gratzinger D, et al. HHV8\/KSHV-Positive Lymphoproliferative Disorders and the Spectrum of Plasmablastic and Plasma Cell Neoplasms: 2015 SH\/EAHP Workshop Report-Part 3. Am J Clin Pathol 2017;147:171-187. https:\/\/doi.org\/10.1093\/ajcp\/aqw218","DOI":"10.1093\/ajcp\/aqw218"},{"key":"10.32074\/1591-951X-351_ref54","doi-asserted-by":"crossref","unstructured":"Nador RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi\u2019s sarcoma-associated herpes virus. Blood 1996;88:645-656.","DOI":"10.1182\/blood.V88.2.645.bloodjournal882645"},{"key":"10.32074\/1591-951X-351_ref55","doi-asserted-by":"crossref","unstructured":"Fan W, Bubman D, Chadburn A, et al. Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association. J Virol 2005;79:1244-1251. https:\/\/doi.org\/10.1128\/JVI.79.2.1244-1251.2005","DOI":"10.1128\/JVI.79.2.1244-1251.2005"},{"key":"10.32074\/1591-951X-351_ref56","doi-asserted-by":"crossref","unstructured":"Klein U, Gloghini A, Gaidano G, et al. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 2003;101:4115-4121. https:\/\/doi.org\/10.1182\/blood-2002-10-3090","DOI":"10.1182\/blood-2002-10-3090"},{"key":"10.32074\/1591-951X-351_ref57","doi-asserted-by":"crossref","unstructured":"Jenner RG, Maillard K, Cattini N, et al. Kaposi\u2019s sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile. Proc Natl Acad Sci U S A 2003;100:10399-10404.","DOI":"10.1073\/pnas.1630810100"},{"key":"10.32074\/1591-951X-351_ref58","doi-asserted-by":"crossref","unstructured":"Panagopoulos D, Victoratos P, Alexiou M, et al. Comparative analysis of signal transduction by CD40 and the Epstein-Barr virus oncoprotein LMP1 in vivo. J Virol 2004;78:13253-13261. https:\/\/doi.org\/10.1128\/JVI.78.23.13253-13261.2004","DOI":"10.1128\/JVI.78.23.13253-13261.2004"},{"key":"10.32074\/1591-951X-351_ref59","doi-asserted-by":"crossref","unstructured":"Minamitani T, Ma Y, Zhou H, et al. Mouse model of Epstein-Barr virus LMP1- and LMP2A-driven germinal center B-cell lymphoproliferative disease. Proc Natl Acad Sci U S A 2017;114:4751-4756. Epub 2017 Mar 28. https:\/\/doi.org\/10.1073\/pnas.1701836114","DOI":"10.1073\/pnas.1701836114"},{"key":"10.32074\/1591-951X-351_ref60","doi-asserted-by":"crossref","unstructured":"Ascoli V, Calabro ML, Giannakakis K, et al. Kaposi\u2019s sarcoma-associated herpesvirus\/human herpesvirus 8-associated polyclonal body cavity effusions that mimic primary effusion lymphomas. Int J Cancer 2006;119:1746-1748; author reply 1749-1750. https:\/\/doi.org\/10.1002\/ijc.21965","DOI":"10.1002\/ijc.21965"},{"key":"10.32074\/1591-951X-351_ref61","doi-asserted-by":"crossref","unstructured":"Petzer AL, Gunsilius E, Hayes M, et al. Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br J Haematol 2002;117:623-625. https:\/\/doi.org\/10.1046\/j.1365-2141.2002.03523.x","DOI":"10.1046\/j.1365-2141.2002.03523.x"},{"key":"10.32074\/1591-951X-351_ref62","doi-asserted-by":"crossref","unstructured":"Ghoneima A, Cooke J, Shaw E, et al. Human herpes virus 8-positive germinotropic lymphoproliferative disorder: first case diagnosed in the UK, literature review and discussion of treatment options. BMJ Case Rep 2020;13: e231640. https:\/\/doi.org\/10.1136\/bcr-2019-231640","DOI":"10.1136\/bcr-2019-231640"},{"key":"10.32074\/1591-951X-351_ref63","doi-asserted-by":"crossref","unstructured":"Bhavsar T, Lee JC, Perner Y, et al. KSHV-associated and EBV-associated Germinotropic Lymphoproliferative Disorder: New Findings and Review of the Literature. Am J Surg Pathol 2017;41:795-800. https:\/\/doi.org\/10.1097\/PAS.0000000000000823","DOI":"10.1097\/PAS.0000000000000823"},{"key":"10.32074\/1591-951X-351_ref64","doi-asserted-by":"crossref","unstructured":"Zanelli M, Fraternali Orcioni G, Zizzo M, et al. HHV-8- and EBV-positive germinotropic lymphoproliferative disorder. Ann Hematol 2019;98:2439-2441. Epub 2019 Aug 3. https:\/\/doi.org\/10.1007\/s00277-019-03773-0","DOI":"10.1007\/s00277-019-03773-0"},{"key":"10.32074\/1591-951X-351_ref65","doi-asserted-by":"crossref","unstructured":"Liu AY, Nabel CS, Finkelman BS, et al. Idiopathic multicentric Castleman\u2019s disease: a systematic literature review. Lancet Haematol 2016;3:e163-175. Epub 2016 Mar 17. https:\/\/doi.org\/10.1016\/S2352-3026(16)00006-5","DOI":"10.1016\/S2352-3026(16)00006-5"},{"key":"10.32074\/1591-951X-351_ref66","doi-asserted-by":"crossref","unstructured":"Kawabata H, Takai K, Kojima M, et al. Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop 2013;53:57-61. https:\/\/doi.org\/10.3960\/jslrt.53.57","DOI":"10.3960\/jslrt.53.57"},{"key":"10.32074\/1591-951X-351_ref67","doi-asserted-by":"crossref","unstructured":"Louis C, Vijgen S, Samii K, et al. TAFRO Syndrome in caucasians: a case report and review of the literature. Front Med (Lausanne) 2017;4:149. https:\/\/doi.org\/10.3389\/fmed.2017.00149","DOI":"10.3389\/fmed.2017.00149"},{"key":"10.32074\/1591-951X-351_ref68","doi-asserted-by":"crossref","unstructured":"Masaki Y, Kawabata H, Takai K, et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Epub 2016 Mar 18. Int J Hematol 2016;103:686-692. https:\/\/doi.org\/10.1007\/s12185-016-1979-1","DOI":"10.1007\/s12185-016-1979-1"},{"key":"10.32074\/1591-951X-351_ref69","doi-asserted-by":"crossref","unstructured":"Masaki Y, Kawabata H, Takai K, et al. 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol 2020;111:155-158. Epub 2019 Nov 28. https:\/\/doi.org\/10.1007\/s12185-019-02780-1","DOI":"10.1007\/s12185-019-02780-1"},{"key":"10.32074\/1591-951X-351_ref70","doi-asserted-by":"crossref","unstructured":"Iwaki N, Fajgenbaum DC, Nabel CS, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 2016;91:220-226. https:\/\/doi.org\/10.1002\/ajh.24242","DOI":"10.1002\/ajh.24242"},{"key":"10.32074\/1591-951X-351_ref71","doi-asserted-by":"crossref","unstructured":"Fujimoto S, Sakai T, Kawabata H, et al. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol 2019;94:975-983. Epub 2019 Jun 21. https:\/\/doi.org\/10.1002\/ajh.25554","DOI":"10.1002\/ajh.25554"},{"key":"10.32074\/1591-951X-351_ref72","doi-asserted-by":"crossref","unstructured":"Nishimura Y, Hanayama Y, Fujii N, et al. Comparison of the clinical characteristics of TAFRO syndrome and idiopathic multicentric Castleman disease in general internal medicine: a 6-year retrospective study. Intern Med J 2020;50:184-191. https:\/\/doi.org\/10.1111\/imj.14404","DOI":"10.1111\/imj.14404"},{"key":"10.32074\/1591-951X-351_ref73","doi-asserted-by":"crossref","unstructured":"Sakashita K, Murata K, Takamori M: TAFRO syndrome: current perspectives. J Blood Med 2018;9:15-23. https:\/\/doi.org\/10.2147\/JBM.S127822","DOI":"10.2147\/JBM.S127822"},{"key":"10.32074\/1591-951X-351_ref74","doi-asserted-by":"crossref","unstructured":"Yu L, Tu M, Cortes J, et al. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood 2017;129:1658-1668. Epub 2017 Jan 18. https:\/\/doi.org\/10.1182\/blood-2016-11-748855","DOI":"10.1182\/blood-2016-11-748855"},{"key":"10.32074\/1591-951X-351_ref75","doi-asserted-by":"crossref","unstructured":"van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 2018;132:2115-2124. Epub 2018 Sep 4. https:\/\/doi.org\/10.1182\/blood-2018-07-862334","DOI":"10.1182\/blood-2018-07-862334"},{"key":"10.32074\/1591-951X-351_ref76","doi-asserted-by":"crossref","unstructured":"Wang HW, Pittaluga S, Jaffe ES. Multicentric Castleman disease: Where are we now? Semin Diagn Pathol 2016;33:294-306. Epub 2016 May 16. https:\/\/doi.org\/10.1053\/j.semdp.2016.05.006","DOI":"10.1053\/j.semdp.2016.05.006"},{"key":"10.32074\/1591-951X-351_ref77","doi-asserted-by":"crossref","unstructured":"Pierson SK, Stonestrom AJ, Shilling D, et al. Plasma proteomics identifies a \u2018chemokine storm\u2019 in idiopathic multicentric Castleman disease. Am J Hematol 2018;93:902-912. Epub 2018 May 16. https:\/\/doi.org\/10.1002\/ajh.25123","DOI":"10.1002\/ajh.25123"},{"key":"10.32074\/1591-951X-351_ref78","doi-asserted-by":"crossref","unstructured":"Yoshimi A, Trippett TM, Zhang N, et al. Genetic basis for iMCD-TAFRO. Oncogene 2020;39:3218-3225. Epub 2020 Feb 12. https:\/\/doi.org\/10.1038\/s41388-020-1204-9","DOI":"10.1038\/s41388-020-1204-9"},{"key":"10.32074\/1591-951X-351_ref79","doi-asserted-by":"crossref","unstructured":"van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2014;15:966-974. Epub 2014 Jul 17. https:\/\/doi.org\/10.1016\/S1470-2045(14)70319-5","DOI":"10.1016\/S1470-2045(14)70319-5"},{"key":"10.32074\/1591-951X-351_ref80","doi-asserted-by":"crossref","unstructured":"Abramson JS. Diagnosis and management of Castleman disease. J Natl Compr Canc Netw 2019;17:1417-1419. https:\/\/doi.org\/10.6004\/jnccn.2019.5037","DOI":"10.6004\/jnccn.2019.5037"},{"key":"10.32074\/1591-951X-351_ref81","doi-asserted-by":"crossref","unstructured":"Fajgenbaum DC, Wu D, Goodman A, et al. Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. Am J Hematol 2020;95:1553-1561. https:\/\/doi.org\/10.1002\/ajh.25992","DOI":"10.1002\/ajh.25992"},{"key":"10.32074\/1591-951X-351_ref82","doi-asserted-by":"crossref","unstructured":"Arenas DJ, Floess K, Kobrin D, et al. Increased mTOR activation in idiopathic multicentric Castleman disease. Blood 2020;135:1673-1684. https:\/\/doi.org\/10.1182\/blood.2019002792","DOI":"10.1182\/blood.2019002792"},{"key":"10.32074\/1591-951X-351_ref83","doi-asserted-by":"crossref","unstructured":"Fajgenbaum DC, Langan RA, Japp AS, et al. Identifying and targeting pathogenic PI3K\/AKT\/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Invest 2019;129:4451-4463. https:\/\/doi.org\/10.1172\/JCI126091","DOI":"10.1172\/JCI126091"},{"key":"10.32074\/1591-951X-351_ref84","doi-asserted-by":"crossref","unstructured":"Stern RM, Berliner N. Targeting the mTOR pathway in idiopathic multicentric Castleman disease. J Clin Invest 2019;129:4086-4088. https:\/\/doi.org\/10.1172\/JCI131332","DOI":"10.1172\/JCI131332"},{"key":"10.32074\/1591-951X-351_ref85","doi-asserted-by":"crossref","unstructured":"Koga T, Hagimori N, Takemori S, et al. Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: study protocol for clinical trial. Medicine (Baltimore) 2020;99:e20710. https:\/\/doi.org\/10.1097\/MD.0000000000020710","DOI":"10.1097\/MD.0000000000020710"},{"key":"10.32074\/1591-951X-351_ref86","doi-asserted-by":"crossref","unstructured":"Vandenbroucke JP: In defense of case reports and case series. Ann Intern Med 2001;134:330-334. https:\/\/doi.org\/10.7326\/0003-4819-134-4-200102200-00017","DOI":"10.7326\/0003-4819-134-4-200102200-00017"},{"key":"10.32074\/1591-951X-351_ref87","doi-asserted-by":"crossref","unstructured":"You L, Lin Q, Zhao J, et al. Whole-exome sequencing identifies novel somatic alterations associated with outcomes in idiopathic multicentric Castleman disease. Br J Haematol 2020;188:e64-e67. Epub 2019 Dec 21. https:\/\/doi.org\/10.1111\/bjh.16330","DOI":"10.1111\/bjh.16330"},{"key":"10.32074\/1591-951X-351_ref88","doi-asserted-by":"crossref","unstructured":"Butzmann A, Kumar J, Sridhar K, et al. A Review of Genetic Abnormalities in Unicentric and Multicentric Castleman Disease. Biology (Basel) 2021;10: 251. https:\/\/doi.org\/10.3390\/biology10040251","DOI":"10.3390\/biology10040251"},{"key":"10.32074\/1591-951X-351_ref89","doi-asserted-by":"crossref","unstructured":"Fajgenbaum DC, Shilling D. Castleman Disease pathogenesis. Hematol Oncol Clin North Am 2018;32:11-21. https:\/\/doi.org\/10.1016\/j.hoc.2017.09.002","DOI":"10.1016\/j.hoc.2017.09.002"},{"key":"10.32074\/1591-951X-351_ref90","doi-asserted-by":"crossref","unstructured":"Wang C, Huang XF, Cai QQ, et al. Remarkable expression of vascular endothelial growth factor in bone marrow plasma cells of patients with POEMS syndrome. Leuk Res 2016;50:78-84. Epub 2016 Sep 26. https:\/\/doi.org\/10.1016\/j.leukres.2016.09.017","DOI":"10.1016\/j.leukres.2016.09.017"},{"key":"10.32074\/1591-951X-351_ref91","doi-asserted-by":"crossref","unstructured":"Chan JK, Fletcher CD, Hicklin GA, et al. Glomeruloid hemangioma. A distinctive cutaneous lesion of multicentric Castleman\u2019s disease associated with POEMS syndrome. Am J Surg Pathol 1990;14:1036-1046. https:\/\/doi.org\/10.1097\/00000478-199011000-00005","DOI":"10.1097\/00000478-199011000-00005"},{"key":"10.32074\/1591-951X-351_ref92","doi-asserted-by":"crossref","unstructured":"Bender S, Javaugue V, Saintamand A, et al. Immunoglobulin variable domain high-throughput sequencing reveals specific novel mutational patterns in POEMS syndrome. Blood 2020;135:1750-1758. https:\/\/doi.org\/10.1182\/blood.2019004197","DOI":"10.1182\/blood.2019004197"},{"key":"10.32074\/1591-951X-351_ref93","doi-asserted-by":"crossref","unstructured":"Dao LN, Hanson CA, Dispenzieri A, et al. Bone marrow histopathology in POEMS syndrome: a distinctive combination of plasma cell, lymphoid, and myeloid findings in 87 patients. Blood 2011;117:6438-6444. Epub 2011 Mar 8. https:\/\/doi.org\/10.1182\/blood-2010-11-316935","DOI":"10.1182\/blood-2010-11-316935"},{"key":"10.32074\/1591-951X-351_ref94","doi-asserted-by":"crossref","unstructured":"Dispenzieri A. POEMS syndrome: 2021 update on diagnosis, risk-stratification, and management. Am J Hematol 2021;96:872-888. Epub 2021 May 31. https:\/\/doi.org\/10.1002\/ajh.26240","DOI":"10.1002\/ajh.26240"},{"key":"10.32074\/1591-951X-351_ref95","doi-asserted-by":"crossref","unstructured":"Khouri J, Nakashima M, Wong S. Update on the diagnosis and treatment of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes) syndrome: a review. JAMA Oncol 2021;7:1383-1391. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0586","DOI":"10.1001\/jamaoncol.2021.0586"},{"key":"10.32074\/1591-951X-351_ref96","unstructured":"Zarate-Osorno A, Medeiros LJ, Danon AD, et al. Hodgkin\u2019s disease with coexistent Castleman-like histologic features. A report of three cases. Arch Pathol Lab Med 1994;118:270-274."},{"key":"10.32074\/1591-951X-351_ref97","doi-asserted-by":"crossref","unstructured":"Shiroshita K, Kikuchi T, Okayama M, et al. Interleukin-6-producing Intravascular large B-cell lymphoma with lymphadenopathy mimicking the histology of multicentric Castleman disease. Intern Med 2020;59:3061-3065. Epub 2020 Aug 4. https:\/\/doi.org\/10.2169\/internalmedicine.5046-20","DOI":"10.2169\/internalmedicine.5046-20"},{"key":"10.32074\/1591-951X-351_ref98","doi-asserted-by":"crossref","unstructured":"Pina-Oviedo S, Miranda RN, Lin P, et al. Follicular lymphoma with hyaline-vascular Castleman-like features: analysis of 6 cases and review of the literature. Hum Pathol 2017;68:136-146. Epub 2017 Sep 2. https:\/\/doi.org\/10.1016\/j.humpath.2017.08.024","DOI":"10.1016\/j.humpath.2017.08.024"},{"key":"10.32074\/1591-951X-351_ref99","doi-asserted-by":"crossref","unstructured":"Sato Y, Kojima M, Takata K, et al. Multicentric Castleman\u2019s disease with abundant IgG4-positive cells: a clinical and pathological analysis of six cases. J Clin Pathol 2010;63:1084-1089. Epub 2010 Oct 24. https:\/\/doi.org\/10.1136\/jcp.2010.082958.","DOI":"10.1136\/jcp.2010.082958"},{"key":"10.32074\/1591-951X-351_ref100","doi-asserted-by":"crossref","unstructured":"Otani K, Inoue D, Fujikura K, et al. Idiopathic multicentric Castleman\u2019s disease: a clinicopathologic study in comparison with IgG4-related disease. Oncotarget 2018;9:6691-6706. https:\/\/doi.org\/10.18632\/oncotarget.24068","DOI":"10.18632\/oncotarget.24068"}],"container-title":["Pathologica"],"original-title":[],"link":[{"URL":"https:\/\/www.pathologica.it\/article\/view\/351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T13:26:23Z","timestamp":1730813183000},"score":1,"resource":{"primary":{"URL":"https:\/\/old.pathologica.it\/article\/view\/351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":100,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,10]]}},"URL":"https:\/\/doi.org\/10.32074\/1591-951x-351","relation":{},"ISSN":["1591-951X"],"issn-type":[{"value":"1591-951X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]},"article-number":"7"}}